Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.

Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi BC, Prukova D, Brezinova J, Michalova K, Vockova P, Hernandez-Ilizaliturri F, Kulvait V, Zivny J, Vokurka M, Necas E, Trneny M, Klener P.

Lab Invest. 2014 Jul;94(7):806-17. doi: 10.1038/labinvest.2014.61. Epub 2014 May 26.

2.

NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.

Verner J, Trbusek M, Chovancova J, Jaskova Z, Moulis M, Folber F, Halouzka R, Mayer J, Pospisilova S, Doubek M.

Leuk Lymphoma. 2015;56(11):3198-206. doi: 10.3109/10428194.2015.1034701. Epub 2015 May 12.

PMID:
25827173
3.

In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1.

Molinský J, Klánová M, Maswabi B, Soukup T, Trněný M, Nečas E, Živný J, Klener P.

Folia Biol (Praha). 2013;59(1):26-31.

4.

Non-obese diabetic-recombination activating gene-1 (NOD-Rag1 null) interleukin (IL)-2 receptor common gamma chain (IL2r gamma null) null mice: a radioresistant model for human lymphohaematopoietic engraftment.

Pearson T, Shultz LD, Miller D, King M, Laning J, Fodor W, Cuthbert A, Burzenski L, Gott B, Lyons B, Foreman O, Rossini AA, Greiner DL.

Clin Exp Immunol. 2008 Nov;154(2):270-84. doi: 10.1111/j.1365-2249.2008.03753.x. Epub 2008 Sep 8.

5.

Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.

Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G, Shultz LD, Bertolini F.

Int J Cancer. 2008 Nov 1;123(9):2222-7. doi: 10.1002/ijc.23772.

6.

A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.

Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q.

Clin Cancer Res. 2008 Apr 1;14(7):2154-60. doi: 10.1158/1078-0432.CCR-07-4409. Erratum in: Clin Cancer Res. 2014 Oct 1;20(19):5142-3.

7.

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.

Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P Jr.

Mol Cancer. 2014 Jun 27;13:159. doi: 10.1186/1476-4598-13-159.

8.

Dendritic cell-based therapy for mantle cell lymphoma.

Munger CM, Vose JM, Joshi SS.

Int J Oncol. 2006 Jun;28(6):1337-43.

PMID:
16685434
9.

Development of a murine model for blastoid variant mantle-cell lymphoma.

Ford RJ, Shen L, Lin-Lee YC, Pham LV, Multani A, Zhou HJ, Tamayo AT, Zhang C, Hawthorn L, Cowell JK, Ambrus JL Jr.

Blood. 2007 Jun 1;109(11):4899-906. Epub 2007 Feb 20.

10.

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA.

Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14.

11.

p110α Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.

Guan J, Huang D, Yakimchuk K, Okret S.

Mol Cancer Ther. 2018 May;17(5):1090-1100. doi: 10.1158/1535-7163.MCT-17-0784. Epub 2018 Feb 26.

12.

Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation.

Gustafsson K, Wang X, Severa D, Eriksson M, Kimby E, Merup M, Christensson B, Flygare J, Sander B.

Int J Cancer. 2008 Sep 1;123(5):1025-33. doi: 10.1002/ijc.23584.

13.

Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.

Teshima K, Nara M, Watanabe A, Ito M, Ikeda S, Hatano Y, Oshima K, Seto M, Sawada K, Tagawa H.

Oncogene. 2014 Apr 24;33(17):2191-203. doi: 10.1038/onc.2013.177. Epub 2013 May 20.

PMID:
23686310
14.

Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells.

Medina DJ, Abass-Shereef J, Walton K, Goodell L, Aviv H, Strair RK, Budak-Alpdogan T.

PLoS One. 2014 Apr 10;9(4):e91042. doi: 10.1371/journal.pone.0091042. eCollection 2014.

15.

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE, Hu Q, Liu S, Klener P, Vockova P, Czuczman MS, Hernandez-Ilizaliturri FJ.

Blood. 2016 Mar 3;127(9):1128-37. doi: 10.1182/blood-2015-04-640920. Epub 2015 Dec 16.

16.

Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.

Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G.

Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31.

17.

Good engraftment of B-cell precursor ALL in NOD-SCID mice.

Baersch G, Möllers T, Hötte A, Dockhorn-Dworniczak B, Rübe C, Ritter J, Jürgens H, Vormoor J.

Klin Padiatr. 1997 Jul-Aug;209(4):178-85.

PMID:
9293448
18.

Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.

Vose JM.

Am J Hematol. 2013 Dec;88(12):1082-8. doi: 10.1002/ajh.23615. Review.

19.
20.

Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome.

Woiterski J, Ebinger M, Witte KE, Goecke B, Heininger V, Philippek M, Bonin M, Schrauder A, Röttgers S, Herr W, Lang P, Handgretinger R, Hartwig UF, André MC.

Int J Cancer. 2013 Oct 1;133(7):1547-56. doi: 10.1002/ijc.28170. Epub 2013 Apr 17.

Supplemental Content

Support Center